Weight and BMI Patterns in a Biologicals-Treated IBD Cohort

• DOI: 10.1007/s10620-022-07488-7
• Publication Date: 2022-04-03T15:02:18Z
• Authors: P. Kaazan; Z. Tan; P. Maiyani; M. Mickenbecker; S. Edwards; C. McIvor; J. M. Andrews
• Keywords: Vedolizumab; Weight change; Ustekinumab

Biologic therapies are effective at inducing and maintaining remission in people with inflammatory bowel disease (IBD). Previous studies have associated TNF-a inhibitors weight gain, however, it is unclear if this a class-specific effect or manifestation of good control. To clarify issue, retrospective study was undertaken to examine changes over time during therapy different biologic agents.Adult patients IBD who received any biological for least 12 months, between 2008 2020, were identified two specialised services. Demographic, disease, therapy-related data examined. Weight change patterns thereof examined each specific relationships amongst outcomes various predictive factors explored.Of 294 (156 females), 165 Infliximab (IFX), 68 Adalimumab (ADA), 36 Vedolizumab (VDZ) 25 Ustekinumab (UST). There statistically significant gain the IFX VDZ groups more vs ADA most points. Three trajectories identified: around 95% had small loss modest but 5% patients, whom on marked (24.3 kg). Having baseline high BMI, being female, having an initiation CRP ≤ 5 albumin > 35 reduced odds major gain.Weight treated appears be clinical (male gender, CRP, low albumin) therapy-specific factors.